Kain K C, Shanks G D, Keystone J S
Centre for Travel and Tropical Medicine, Division of Infectious Diseases, Department of Medicine, Toronto General Hospital and University of Toronto, Toronto, Ontario, Canada.
Clin Infect Dis. 2001 Jul 15;33(2):226-34. doi: 10.1086/321817. Epub 2001 Jun 14.
As international travel becomes increasingly common and resistance to antimalarial drugs escalates, a growing number of travelers are at risk for contracting malaria. Parasite resistance to chloroquine and proguanil and real or perceived intolerance among patients to standard prophylactic agents such as mefloquine have highlighted the need for new antimalarial drugs. Promising new regimens include atovaquone and proguanil, in combination; primaquine; and a related 8-aminoquinoline, tafenoquine. These agents are active against the liver stage of the malaria parasite and therefore can be discontinued shortly after the traveler leaves an area where malaria is endemic, which encourages adherence to the treatment regimen. Part 1 of this series reviews currently recommended chemoprophylactic drug regimens, and part 2 will focus on 8-aminoquinoline drugs.
随着国际旅行日益普遍以及疟原虫对抗疟药物的耐药性不断增强，越来越多的旅行者面临感染疟疾的风险。疟原虫对氯喹和氯胍产生耐药性，以及患者对诸如甲氟喹等标准预防药物实际存在或感觉不耐受，凸显了对新型抗疟药物的需求。有前景的新疗法包括阿托伐醌和氯胍联合使用、伯氨喹以及一种相关的8-氨基喹啉他非诺喹。这些药物对疟原虫的肝脏阶段有活性，因此旅行者离开疟疾流行地区后不久即可停药，这有助于提高对治疗方案的依从性。本系列的第1部分回顾了目前推荐的化学预防药物疗法，第2部分将重点介绍8-氨基喹啉类药物。
